PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884079
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1884079
GLP-2 Analogs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of GLP-2 analogs Market
The global GLP-2 analogs market continues to expand rapidly as the burden of short bowel syndrome (SBS) and other gastrointestinal disorders grows worldwide. According to the latest assessment, the market was valued at USD 1.05 billion in 2024, driven by increased diagnosis rates, improving intestinal failure management, and rising clinical acceptance of GLP-2 analog-based therapies. Owing to strong demand for effective SBS treatment options and innovations in long-acting formulations, the market is projected to increase to USD 1.20 billion in 2025, eventually reaching USD 2.83 billion by 2032, reflecting a significant rise in global adoption.
GLP-2 analogs function by mimicking the natural GLP-2 hormone to enhance intestinal growth, promote absorption, and reduce reliance on parenteral nutrition. These therapies have become a cornerstone in managing SBS, offering improved patient outcomes and reducing hospitalization needs associated with chronic intestinal failure. With the U.S., Europe, and Asia Pacific intensifying research and development efforts, the demand for these drugs continues to escalate.
Market Dynamics
Drivers
A primary driver is the increasing prevalence of short bowel syndrome, caused by congenital defects, gastrointestinal surgeries, trauma, or diseases leading to intestinal loss. Rising survival rates and improved awareness have expanded the SBS patient pool requiring long-term treatment. According to Nutrition in Clinical Practice (2025), SBS prevalence in 2024 reached 2.74 per 100,000 adults and 1.67 per 100,000 children, demonstrating a growing global need for effective therapies. As GLP-2 analogs offer clinically proven improvements in intestinal absorption, demand is expected to remain strong across the forecast period.
Restraints
Despite their benefits, high treatment costs remain a significant barrier. The annual cost of Teduglutide therapy exceeds USD 400,000 per patient, limiting accessibility in lower-income regions and creating financial strain even in developed markets. High research and development expenses further contribute to pricing challenges, potentially slowing market penetration.
Opportunities
A promising opportunity lies in the development of long-acting GLP-2 analogs, designed for weekly rather than daily dosing. Products such as Apraglutide and Glepaglutide aim to improve patient compliance and convenience. Zealand Pharma's pipeline, including ready-to-use aqueous analogs, has shown substantial clinical promise, signaling an upcoming wave of next-generation treatments with enhanced efficacy and fewer injections.
Challenges
Regulatory hurdles remain a key challenge as new analogs undergo complex safety evaluations. Concerns over adverse effects-such as gastrointestinal discomfort, pancreatitis, and thyroid cancer-necessitate stringent monitoring and lengthy approval processes. For example, in December 2024, the U.S. FDA issued a complete response letter for Zealand Pharma's Glepaglutide, delaying its entry into the market.
Market Trends
One notable trend is the shift from total parenteral nutrition (TPN) to GLP-2-based therapies. While TPN was historically the primary treatment for SBS, its high complication risks and cost have pushed clinicians toward pharmacological solutions that improve intestinal function. Additionally, ongoing clinical trials are expanding therapeutic indications beyond SBS, with research exploring use in Crohn's disease, ulcerative colitis, chemotherapy-induced enteropathy, and graft-versus-host disease.
Segmentation Insights
By Drug
Teduglutide dominated the market in 2024 and remains the leading GLP-2 analog due to proven safety, clinical efficacy, and widespread adoption. It is the first GLP-2 analog demonstrating reduced dependence on parenteral support. Meanwhile, emerging analogs such as Apraglutide and Glepaglutide are projected to gain traction as long-acting alternatives.
By Route of Administration
The parenteral segment held the largest share in 2024, as most approved GLP-2 analogs are administered by injection. Oral formulations are gaining interest, with Entera Bio's 2024 positive pharmacokinetic results indicating future potential for easier-to-use alternatives.
By Distribution Channel
Online and retail pharmacies led the market in 2024 due to convenience and broad accessibility, while hospital pharmacies remain essential for acute SBS management.
Regional Outlook
North America dominated the GLP-2 analogs market with USD 0.81 billion in 2024, representing the highest adoption and strongest clinical usage of approved analogs. In the U.S., patent expiry for Teduglutide and new clinical trial successes, such as Ironwood's 2024 Apraglutide phase 3 results, continue to stimulate growth.
Europe maintains a strong share due to high research output and supportive regulatory environments. The Asia Pacific region is expanding rapidly, supported by increasing rare disease research and early-stage clinical trials in Japan, China, and South Korea. Latin America and the Middle East & Africa show steady progression as awareness and diagnostic capabilities improve.
Conclusion
The global GLP-2 analogs market is poised for robust growth through 2032 as clinical innovation, long-acting formulations, and expanding disease indications transform SBS management. With the market rising from USD 1.05 billion in 2024 to USD 2.83 billion by 2032, GLP-2 therapies are becoming critical to improving outcomes and reducing the long-term burden of intestinal failure.
Segmentation By Drug
- Teduglutide
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Online & Retail Pharmacies
By Geography
- North America (By Drug, Route of Administration, Distribution Channel, and Country/ Sub-region)
- U.S.
- Canada
- Europe (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- South Korea
- Rest of Asia Pacific
- Latin America (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Short Bowel Syndrome, By Key Countries, 2024
- 4.2. Pipeline Analysis, By Key Players
- 4.3. New Product Launches, By Key Players
- 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
- 4.5. Regolatory and Reimbursement Scenario, By Key Countries/Region
5. Global GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Drug
- 5.1.1. Teduglutide
- 5.1.2. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Online & Retail Pharmacies
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Drug
- 6.1.1. Teduglutide
- 6.1.2. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Online & Retail Pharmacies
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Drug
- 7.1.1. Teduglutide
- 7.1.2. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Online & Retail Pharmacies
- 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Drug
- 8.1.1. Teduglutide
- 8.1.2. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Online & Retail Pharmacies
- 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Drug
- 9.1.1. Teduglutide
- 9.1.2. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Online & Retail Pharmacies
- 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
10. Middle East & Africa GLP-2 Analogs Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Drug
- 10.1.1. Teduglutide
- 10.1.2. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.3.1. Hospital Pharmacies
- 10.3.2. Online & Retail Pharmacies
- 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. Nestle
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Takeda Pharmaceutical Company Limited
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. OxThera
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Zealand Pharma
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Ironwood
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Hanmi Pharm Co., Ltd.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Jaguar Health
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Merck KGaA
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. EnteraBio Ltd.
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. Nestle
List of Tables
- Table 1: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
- Table 2: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 3: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 4: Global GLP-2 Analogs Market Revenue (USD billion) Forecast, by Region, 2019-2032
- Table 5: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
- Table 6: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 7: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 8: North America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 9: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
- Table 10: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 11: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 12: Europe GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 13: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
- Table 14: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 15: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 16: Asia Pacific GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 17: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
- Table 18: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 19: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 20: Latin America GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 21: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Drug, 2019-2032
- Table 22: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 23: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 24: Middle East & Africa GLP-2 Analogs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
List of Figures
- Figure 1: Global GLP-2 Analogs Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
- Figure 2: Global GLP-2 Analogs Market Value Share (%), by Drug, 2024 & 2032
- Figure 3: Global GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024 & 2032
- Figure 4: Global GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024 & 2032
- Figure 5: Global GLP-2 Analogs Market Value Share (%), by Region, 2024 & 2032
- Figure 6: North America GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
- Figure 7: North America GLP-2 Analogs Market Value Share (%), by Drug, 2024
- Figure 8: North America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 9: North America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
- Figure 10: North America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 11: North America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
- Figure 12: North America GLP-2 Analogs Market Value (USD billion), By Country, 2024 & 2032
- Figure 13: North America GLP-2 Analogs Market Value Share (%), By Country, 2024
- Figure 14: Europe GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
- Figure 15: Europe GLP-2 Analogs Market Value Share (%), by Drug, 2024
- Figure 16: Europe GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 17: Europe GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
- Figure 18: Europe GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 19: Europe GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
- Figure 20: Europe GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 21: Europe GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2024
- Figure 22: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
- Figure 23: Asia Pacific GLP-2 Analogs Market Value Share (%), by Drug, 2024
- Figure 24: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 25: Asia Pacific GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
- Figure 26: Asia Pacific GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 27: Asia Pacific GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
- Figure 28: Asia Pacific GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 29: Asia Pacific GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2024
- Figure 30: Latin America GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
- Figure 31: Latin America GLP-2 Analogs Market Value Share (%), by Drug, 2024
- Figure 32: Latin America GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 33: Latin America GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
- Figure 34: Latin America GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 35: Latin America GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
- Figure 36: Latin America GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 37: Latin America GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2024
- Figure 38: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Drug, 2024 & 2032
- Figure 39: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Drug, 2024
- Figure 40: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 41: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Route of Administration, 2024
- Figure 42: Middle East & Africa GLP-2 Analogs Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 43: Middle East & Africa GLP-2 Analogs Market Value Share (%), by Distribution Channel, 2024
- Figure 44: Middle East & Africa GLP-2 Analogs Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 45: Middle East & Africa GLP-2 Analogs Market Value Share (%), By Country/ Sub-region, 2024
- Figure 46: Global GLP-2 Analogs Market Share (%), By Company, 2024
